Expert Interview
Discussing Anaphylm (AQST-109) and its ongoing EPIPHAST II trial comparing it to EpiPen and a generic epinephrine injection.
Ticker(s): AQSTInstitution: University of Pennsylvania/CHOP
- Allergy & Immunology specialist at the Children's Hospital of Philadelphia.
- Manages 400 patients a year for anaphylactic shock.
- Research interest in environmental and food allergies, Immunodeficiency in Cornelia de Lange syndrome and other genetic syndromes.
How many patients do you manage for Anaphylactic Shock?
Added By: ben_adminWhat are your thoughts on the potential of AQST-109?
Added By: ben_adminHow does AQST-109 compare to the Epipen and other epinephrine medications?
Added By: ben_adminWill patients prefer a needle-free, orally administered epinephrine medication?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
